To test whether VEGF signalling downstream of loss of Krit1 is involved in CCM pathogenesis, we treated Krit1ieKO mice with 3 mg/kg of the VEGFR2 inhibitor SU5416 twice weekly until 4 months of age, starting at P14. This evidence concerns the gene KRIT1 and cerebral cavernous malformation.